Erratum: Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: Real-world data from an Italian managed access program (American Journal of Clinical Oncology: Cancer Clinical Trials (2019) 42 (42-45) DOI: 10.1097/COC.0000000000000478)

In "Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program," which published in the January 2019 issue, the authors would like to make a few corrections. In the background it was wrongly stated that in the METEOR trial the median progression free survival (mPFS) of Everolimus was 3.08 months, but actually the real mPFS of everolimus arm was 3.8 months.1 In the treatment section and within the abstract, it was stated that Cabozantintib was administered in a 28 days cycles whereas its labeled administration is in continuous treatment. Furthermore, it was specified: "A lower starting dose of 40 mg were prescribed in patients in worse clinical conditions with a dose escalation to 60 mg in case of good tolerance." Actually, dose reescalation must be considered as off-lable use of the drug.2 Moreover, in the results section data were wrongly reported: the sentence "66 years (range, 46 to 83 y)" should read "65 years (range 41-84 y); the sentence "Three (18%) patients were diagnosed with type II papillary RCC, 9 (53%) type I papillary, 3 (18%) chromophobe, and 2 (11%) with Bellini duct carcinoma" should read "Three (18%) patients were diagnosed with type I papillary RCC, 9 (53%) type II papillary, 3 (18%) chromophobe, and 2 (11%) with Bellini duct carcinoma"; the sentence "Cabozantinib was administered as second-line therapy in 5 (30%) patients, as third line in 2 (11%) patients and in the remaining 10 (59%)" should read "Cabozantinib was administered as second line therapy in 1 (6%) patients, as third line in 4 (24%) patients and in the remaining 12 (70%)". In Table 1 the line "Line of treatment" should read "Previous lines of treatment".